{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T07:41:17Z","timestamp":1783496477100,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jpba.2017.07.060","type":"journal-article","created":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T18:17:28Z","timestamp":1501611448000},"page":"651-660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Identification and determination of related substances of ceftaroline fosamil in medicinal product by high performance liquid chromatography with diode array detection and tandem mass spectrometry"],"prefix":"10.1016","volume":"145","author":[{"given":"Izabela","family":"Karpiuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Michalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Bus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kiljan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Tyski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2017.07.060_bib0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ijantimicag.2011.01.017","article-title":"Ceftaroline: a comprehensive update","volume":"37","author":"Kaushik","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jpba.2017.07.060_bib0010","series-title":"Summary Review for FDA Approved Drug Product NDA 200\u2013327, Ceftaroline Fosamil 400\u2009mg and 600\u2009mg for Injection (tradename: Teflaro \u2122)","author":"U.S. Food Drugs","year":"2017"},{"key":"10.1016\/j.jpba.2017.07.060_bib0015","series-title":"Authorisation Details of Zinforo\u2122, Agency Product Number: EMEA\/H\/C\/002252, Ceftaroline Fosamil, AstraZeneca AB","year":"2017"},{"key":"10.1016\/j.jpba.2017.07.060_bib0020","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/S0968-0896(03)00126-3","article-title":"TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties","volume":"11","author":"Ishikawa","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jpba.2017.07.060_bib0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2165\/00003495-200969070-00003","article-title":"Ceftaroline: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus","volume":"69","author":"Zhanel","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2017.07.060_bib0030","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.biotechadv.2012.12.001","article-title":"recent advances in the biosythesis of pencilins, cephalosporins and clavams and its regulation","volume":"31","author":"Ozcengiz","year":"2013","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.jpba.2017.07.060_bib0035","first-page":"1684","article-title":"Degradation of \u03b2-lactam antibiotics","volume":"87","author":"Deshpande","year":"2004","journal-title":"Curr. Sci."},{"key":"10.1016\/j.jpba.2017.07.060_bib0040","unstructured":"T. Ishikawa, S. Hashiguchi, Y. Iizawa, Patent Application Pub. No.: WO099\/32497; Pub. Date: 01.07.1999; Phosphonocephem derivatives, process for the preparation of the same, and use thereof. Takeda Chemicals Industries, Ltd. (Patent No.: US 6, 417, 175 B1)."},{"key":"10.1016\/j.jpba.2017.07.060_bib0045","unstructured":"K. Mohammad, B.P. Rai, N. Tewari, Patent Application Pub. No.: WO 2013\/084171 A1; Pub. Date: 13.06.2013; Process for preparing ceftaroline salts or hydrates thereof. Ranbaxy Laboratories Limited (Patent No.: US 2014\/0350240 A1)."},{"key":"10.1016\/j.jpba.2017.07.060_bib0050","unstructured":"Patent Application Pub. No.: CN 104163803 A; Pub. Date: 26.11.2014; Synthesis method of ceftaroline fosamil; Warwick Nanjing Pharmaceutical Technology Development Co., Ltd."},{"key":"10.1016\/j.jpba.2017.07.060_bib0055","first-page":"63","article-title":"Development and validation of UV spectrophotometric method for quantitative estimation of ceftaroline fosamil in bulk and injection form","volume":"2","author":"Suneetha","year":"2012","journal-title":"Int. J. Pharm. Res. Anal."},{"key":"10.1016\/j.jpba.2017.07.060_bib0060","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/392130","article-title":"Development and validation of stability indicating RP-HPLC method for estimation of ceftaroline fosamil in bulk and its parenteral dosage forms","author":"Suneetha","year":"2013","journal-title":"ISRN Anal. Chem."},{"key":"10.1016\/j.jpba.2017.07.060_bib0065","first-page":"97","article-title":"Stability indicating RP-HPLC method for the ceftaroline fosamil acetate","volume":"5","author":"Sharma","year":"2013","journal-title":"Hygeia. J. D. Med."},{"key":"10.1016\/j.jpba.2017.07.060_bib0070","first-page":"929","article-title":"Development and validation of analytical method for the estimation of ceftaroline fosamil in bulk and pharmaceutical dosage form by RP-HPLC","volume":"4","author":"Ali","year":"2015","journal-title":"WJPPS"},{"key":"10.1016\/j.jpba.2017.07.060_bib0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpba.2015.10.008","article-title":"Simultaneous determination of ceftaroline, daptomycin, linezolid and rifampicin concentrations in human plasma by on-line solid phase extraction coupled to high-performance liquid chromatography-tandem mass spectrometry","volume":"118","author":"Gr\u00e9goire","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2017.07.060_bib0080","series-title":"ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology Q2 (R1), Current Step 4 Version","year":"2005"},{"key":"10.1016\/j.jpba.2017.07.060_bib0085","series-title":"Encycl. Sep. Sci.","first-page":"4063","article-title":"Quantitative structure-retention relationships (QSRR) in chromatography","author":"Kaliszan","year":"2000"},{"key":"10.1016\/j.jpba.2017.07.060_bib0090","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00216-014-8317-3","article-title":"Artificial neural network prediction of multilinear gradient retention in reversed-phase HPLC: comprehensive QSRR-based models combining categorical or structural solute descriptors and gradient profile parameters","volume":"407","author":"D\u2019Archivio","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2017.07.060_bib0095","series-title":"ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances Q3A(R2), Current Step 4 Version","year":"2006"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851731186X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073170851731186X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T11:59:47Z","timestamp":1536321587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073170851731186X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":19,"alternative-id":["S073170851731186X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2017.07.060","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification and determination of related substances of ceftaroline fosamil in medicinal product by high performance liquid chromatography with diode array detection and tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2017.07.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}